Desk› Healthcare› Natco Pharma Ltd

Natco Pharma Ltd

BSE 524816 NATCOPHARM INE987B01026

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 60 trading days

22 filings · 13 material · busiest 2026-08-14

What it files

Press Release4 Analyst / Investor Meet4 Investor Presentation2 Concall Transcript2 Board Meeting2 Change in Management2 Board Outcome1 Dividend1

Filings

22 in the window

25 August 2026

Press Release

Press Release / Media Release

Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.

Company Update / Press Release / Media Release View filing →
24 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Investor Meet

Company Update / Analyst / Investor Meet View filing →
21 August 2026

Press Release

Press Release / Media Release

Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit

Company Update / Press Release / Media Release View filing →
19 August 2026

Investor Presentation

Investor Presentation

Investor Presentation

Company Update / Investor Presentation View filing →
19 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Investor Meet

Company Update / Analyst / Investor Meet View filing →
18 August 2026

Concall Transcript

Earnings Call Transcript

Q1FY2026-27 Transcript for the Earnings call held on 14th August, 2026

Company Update / Earnings Call Transcript View filing →
14 August 2026

Board Outcome

Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting

Board Meeting / Outcome of Board Meeting View filing →
14 August 2026

Dividend

Corporate Action-Board approves Dividend

Board of Directors at their Meeting held on today i.e. 14th August, 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each

Corp. Action / Dividend View filing →
14 August 2026

Investor Presentation

Investor Presentation

Investor Presentation for the Q1FY27

Company Update / Investor Presentation View filing →
14 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-27

Company Update / Analyst / Investor Meet View filing →
11 August 2026

Board Meeting

Update on board meeting

Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation ....

Board Meeting / Board Meeting View filing →
11 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

The Company will host an Earnings Call with Investors / Analysts on Friday, the 14th August, 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ....

Company Update / Analyst / Investor Meet View filing →
6 August 2026

Board Meeting

Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th June, 2026 And Declare Interim Dividend, If Any

Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....

Board Meeting / Board Meeting View filing →
14 July 2026

Order / Contract

Award_of_Order_Receipt_of_Order

Order passed by Assistant Commissioner (ST)(FAC), Tenali Circle, Tenali, Andhra Pradesh

Company Update / Award of Order / Receipt of Order View filing →
14 July 2026

Press Release

Press Release / Media Release

Natco Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram holdings Proprietary Limited

Company Update / Press Release / Media Release View filing →
9 July 2026

Compliance Certificate

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Compliance Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018

Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
8 July 2026

Outcome

Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting

Others / Outcome without intimation View filing →
6 July 2026

Change in Management

Change in Management

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Company Update / Change in Management View filing →
30 June 2026

Trading Window

Closure of Trading Window

Closure of Trading Window

Insider Trading / SAST / Closure of Trading Window View filing →
30 June 2026

Change in Management

Change in Management

Superannuation of Mr. N. Malleswara Rao, Vice President - Operations, Pharma Division, Kothur w.e.f. closure of business hours on 30th June, 2026

Company Update / Change in Management View filing →
4 June 2026

Concall Transcript

Earnings Call Transcript

Earning call Transcript for the concall held on May 29, 2026

Company Update / Earnings Call Transcript View filing →
3 June 2026

Press Release

Press Release / Media Release

NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection

Company Update / Press Release / Media Release View filing →